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of Medicine, NYU Langone Medical Center, New York, NY
*Division of Cardiology and Department of Medicine, Massachusetts General Hospital and 
Harvard Medical School, Boston, MA
The benefit of revascularization in stable ischemic heart disease patients is 
controversial; a better method for patient selection is needed
Over thirty years ago, a benefit of surgical revascularization was demonstrated in patients 
with stable ischemic heart disease (SIHD) but this was before most of our current disease-
modifying medical therapies for coronary artery disease (CAD) were available.1 Analysis of 
these trials indicated that patients who derived the most benefit from surgery were those 
with more extensive CAD, particularly those with significant left main CAD or multivessel 
CAD including proximal left anterior descending stenosis. After the introduction of 
percutaneous coronary intervention (PCI), studies were performed in the 1990s comparing 
PCI to contemporary medical therapy and found no benefit on death, myocardial infarction 
or revascularization2. It was at the time unclear whether this was due to the different 
revascularization technique or advances in medical therapy.
Subsequently, two large, randomized, multi-center trials were undertaken to determine 
whether revascularization offered an advantage over intensive medical therapy (“optimal 
medical therapy”, OMT). The COURAGE and BARI-2D trials randomized patients with 
stable ischemic heart disease to a strategy of routine revascularization in addition to OMT or 
to a strategy of OMT alone.3, 4 The OMT approach included statin-based lipid lowering 
therapy with a target LDL 60–85 mg/dl, anti-ischemic medications alone or in combination 
and angiotensin converting enzyme inhibition or angiotensin receptor blockade. The 
COURAGE trial included 2,287 patients and utilized PCI as the revascularization technique. 
There was no benefit on the primary endpoint of death or myocardial infarction (MI) for the 
routine PCI strategy over a median 4.6 years of follow up and there was also no difference 
between groups in survival. The BARI-2D trial included 2,368 patients with diabetes and 
both PCI and surgery were used for revascularization. Randomization was stratified based 
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on declared physician preference for PCI or CABG after review of the coronary anatomy. 
Again, there were no benefits of the routine revascularization strategy for either the PCI 
stratum or the CABG stratum on survival over an average follow up of 5.3 years. Both 
studies found an early, significant benefit of revascularization on angina relief but by 1–2 
years of follow up, the majority of patients were asymptomatic regardless of treatment 
assignment and the duration of benefit of revascularization on angina was limited to 1–3 
years.5, 6 Details of these studies are summarized in Table 1.
In contrast to the older randomized trials of CABG, analysis of COURAGE and BARI-2D 
did not identify a subgroup that benefitted from PCI based on number of vessels diseased, 
presence of proximal LAD disease or clinical characteristics. 3, 4, 8, 9 Therefore, after these 
studies, selection for revascularization based on coronary anatomic features other than left 
main CAD, which was an exclusion criterion for both, appears to be inappropriate.
Still some physicians continue to believe that there are stable ischemic heart disease patients 
other than those with refractory symptoms or left main disease who may benefit from a 
routine revascularization strategy. Because COURAGE and BARI-2D randomized patients 
after angiography, selection bias based on anatomic and clinical features of the screened 
patients was likely in some cases. This post-cath enrollment approach, while absolutely 
necessary at the time, does limit the implementation of the guideline-determined medical 
therapy alone strategy and also may limit insight into the relationship between anatomic 
features and outcomes by treatment assignment. Strict interpretation of the findings would 
indicate they only apply to patients for whom a physician had equipoise about 
revascularization after viewing the coronary anatomy. Patient beliefs about the benefits of 
revascularization once they have been told about coronary stenosis may limit physician 
ability to implement guideline-determined medical therapy.10, 11
Mortality risk among patients enrolled in COURAGE and BARI-2D was relatively low and 
it remains unknown whether results would have been different if the trials had been carried 
out in cohorts at higher risk. Angina was not a marker of risk in BARI-2D.12 If 
revascularization is effective at improving survival and reducing events in any patients with 
SIHD, many people believe that it is likely those patients at higher risk will receive the most 
benefit. However, the same argument was put forward regarding diabetes and risk before the 
publication of BARI-2D. Therefore the challenge is to identify a clinical characteristic that 
will help physicians select those patients who would have lower risk of death or myocardial 
infarction with a routine revascularization approach.
Why has ischemia burden been suggested as a method of targeting 
revascularization?
Ischemic burden has repeatedly been identified as a powerful prognostic factor among 
patients referred for stress testing using nuclear imaging13–20 echocardiography21–24 and, 
more recently, cardiac MRI (CMR).25–27
It is notable that both COURAGE and BARI-2D entry criteria required evidence of 
ischemia, but the evidence could be as limited as exercise electrocardiographic changes, a 
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limited perfusion defect or a stenosis of ≥70–80% plus classic angina.3, 4 Among the 60% of 
patients enrolled in COURAGE after nuclear stress imaging, most had less than moderate 
ischemia.28 It has been suggested this could have contributed to the neutral overall results of 
the trial.
Observational data from the Cedars-Sinai nuclear registry published by the author of the pro 
viewpoint in this debate20 suggest that selection for revascularization based on ischemia 
burden may be a reasonable approach. In this study including over 10,000 patients referred 
for stress perfusion imaging at a single center, there were nearly 150 cardiac deaths and 
nearly 500 acute coronary syndrome events over an average 2-year follow up. The authors 
plotted the hazard ratio for cardiac death against the percent total ischemic myocardium 
separately for patients who were selected for revascularization within 60 days of stress 
testing and patients who were treated with medical therapy alone. The curves cross such that 
below 10% ischemic myocardium, patients who were treated with medical therapy alone had 
better outcomes than those selected for revascularization while the opposite relationship was 
observed for patients with greater than 10% of the myocardium ischemic. The threshold of 
10% ischemic myocardium is commonly used to denote moderate ischemia on nuclear 
imaging. However, the confidence intervals on these estimates are wide and confidence 
bounds overlap over the entire range of percent ischemic myocardium. Although these data 
lend themselves easily to translation into clinical practice, there is ample reason for caution. 
This was a single center study conducted at a highly skilled nuclear imaging center. Though 
the authors included a propensity score for revascularization in their multivariate modeling, 
the fact that only 10% of the cohort overall and just 39% of the patients with >10% 
myocardium ischemic were selected by physicians for revascularization indicates that the 
decision to revascularize is, and likely should be, made based on more than the ischemic 
burden alone. Data from the multi-center SPARC registry showing that only 48% of patients 
with moderate-severe ischemia were referred for cardiac catheterization similarly suggest 
that multiple factors are taken into account when considering revascularization.29 Lastly, 
medical treatment of the patients was not specified by a protocol and based on the years 
when the study was conducted, was unlikely to have included routine use of medical therapy 
now considered optimal, such as high intensity statins.
The study mentioned above is characteristically cited in articles referring to the potential 
benefit of revascularization based on ischemia severity. An observational study of ischemia 
severity by stress echo also found that selection for revascularization was associated with 
better outcome among those patients with the most severe ischemia. However, the degree of 
ischemia at which selection for revascularization was associated with improved outcomes 
was quite severe, with an average wall motion score index indicating >8 segments 
ischemic.30 Therefore this study, while also large (including over 3,000 patients), has the 
same limitation of potential for bias in selection for revascularization as in the study by 
Hachamovitch et al. Another study comparing different stress echo techniques found no 
relationship between treatment with revascularization or ischemia severity and risk of death 
or MI31 but did not assess risk by the degree of ischemia and selection for revascularization. 
There is no similar analysis to our knowledge using stress CMR, though it is possible to 
identify stress echo and stress CMR criteria which result in approximately the same risk 
level as that associated with 10% left ventricular ischemia on SPECT. 32
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Revascularization appears to reduce ischemia but no randomized data 
show a favorable impact on hard outcomes
The effects of medical therapy and revascularization on ischemic burden were evaluated in 
ancillary studies to COURAGE33 and BARI-2D.34 Among patients enrolled in the 
COURAGE ancillary study who underwent stress imaging both at baseline and again after 
6–18 months, assignment to the routine PCI strategy was associated with a greater 
likelihood of reduction in the amount of ischemia by 5% of the myocardium.33 
Approximately one-third of participants in the ancillary study had moderate-severe ischemia 
at baseline based on core lab interpretation, among whom the routine PCI strategy also 
resulted in a greater likelihood of reduction in ischemia (78% vs. 52%, p=0.007). Similarly, 
patients assigned to medical therapy alone in BARI-2D were more likely to have moderate-
severe ischemia on a one-year nuclear scan compared to either revascularization stratum.
If PCI reduces adverse outcomes in patients with SIHD and moderate-severe ischemia, 
many would presume it does so via reduction in the amount of myocardial ischemia. In the 
BARI-2D nuclear ancillary study, severity of residual ischemia was not an independent 
predictor of outcome after adjustment for an array of clinical variables. The amount of 
scarred myocardium did remain a predictor of outcome after adjustment. Change in ischemia 
burden from baseline was not available. 34 However, evaluation of outcomes by treatment 
assignment within the COURAGE nuclear ancillary study failed to show a benefit for PCI 
among those with moderate-severe ischemia at baseline, when all patients with baseline 
scans were included, regardless of whether they returned for a second test 6–18 months later 
(Figure 1).28 Furthermore, the degree of ischemia in that cohort was not associated with risk 
of events. It must be recognized that power was severely limited in this analysis, which was 
not pre-specified and may have been affected by selection bias. However, consistent with 
this analysis, a recent study including patients with ischemia late after revascularization by 
the author of the pro viewpoint demonstrated similar outcomes for those selected to undergo 
repeat revascularization or medical therapy alone.35 In addition, there was no interaction 
between ischemia at baseline and treatment assignment on outcome, as well as no 
independent relationship between baseline ischemia and outcome, in the randomized 
Surgical Treatment for IsChemic Heart Failure (STICH) trial.36 Furthermore, a recent meta-
analysis of randomized trials of PCI with medical therapy vs. medical therapy in patients 
with ischemia based on stress testing or fractional flow reserve (FFR) found no benefit with 
PCI on mortality and a trend toward higher rates of nonfatal MI in those assigned to PCI.37
Finally, it has been suggested that the improved outcomes observed with the use of FFR-
directed PCI as compared to anatomic guidance of PCI in the FAME and DEFER 
randomized trials38, 39 indicate that ischemia as defined by low FFR identifies candidates for 
revascularization. Neither of these studies included a control group treated with medical 
therapy alone. We agree that FFR is an important consideration when evaluating which 
lesions should be intervened upon when a patient is judged to need revascularization on 
clinical grounds, e.g. symptoms. However, just as is the case for stress test abnormalities, 
patients should not be selected for revascularization solely on the basis of abnormal FFR. 
The results of the multicenter FAME 2 study support this notion.7 Patients referred for PCI 
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and found to have at least one vessel with abnormal FFR were randomized in FAME 2 to 
FFR-guided PCI or medical therapy alone. While the FFR-guided PCI arm was favored on 
comparison of the primary endpoint of death, MI and target vessel revascularization, this 
finding was driven by urgent target vessel revascularization. There was no difference in the 
rate of death or MI between the randomized treatment arm or between either arm and a 
registry of patients who had been referred for PCI but had normal FFR, with the caveat that 
the study was terminated prematurely by the data and safety monitoring board for the 
composite endpoint. The indication for PCI in follow up was unstable angina without ECG 
changes in over half of patients who crossed over to PCI in this study and this rate of PCI 
must be considered in the context of physician and patient awareness of anatomic details and 
FFR results in an unblinded study. Thus the value of ischemia burden by FFR as compared 
to medical therapy alone may be limited to reducing unplanned revascularization. If the 
primary endpoints of COURAGE and BARI 2D had included revascularization they too 
would have reported benefit for the prompt revascularization strategy.
In summary, though revascularization appears to reduce ischemic burden, randomized trial 
data have not demonstrated that this translates into improvement of hard outcomes.
How can we reconcile the prognostic impact of ischemia burden and a 
greater reduction in ischemia burden after revascularization with the 
overall neutral results of COURAGE and BARI-2D?
It is to a certain extent counterintuitive that randomized trials of a routine revascularization 
strategy for stable ischemic heart disease have not demonstrated reductions in death or MI 
despite interventions that “fix” or bypass stenosis and relieve ischemia.
Excess risk associated with a greater burden of ischemia could be due to adverse effects of 
ischemia itself, perhaps in combination with an increased risk of arrhythmia, but could be 
due to other factors. It is possible that increased risk associated with a greater burden of 
ischemia is ultimately due to a greater burden of atherosclerosis in patients with more 
ischemia. A subset analysis of COURAGE found that extent of disease was a predictor of 
outcome in COURAGE while ischemia severity was not.40 Atherosclerosis is a diffuse 
disease and medical therapy, particularly statin therapy, stabilizes plaques. Statins were not 
utilized in earlier randomized trials of CABG and the plaque stabilizing effects of medical 
therapy may be the primary reason underlying differences between these older trials and the 
more recent trial results, particularly considering that in both COURAGE and BARI-2D, 
there was no anatomic subset identified with a benefit from routine PCI.7,41 In the 
PROSPECT study, severely stenotic lesions comprised only 5% of those lesions destined to 
cause acute coronary syndrome while approximately two-thirds of future culprit lesions 
were of mild degree at baseline.42 Several previous angiographic studies also showed that 
the majority of culprit lesions for MI were mild plaques before the event.43–47 For this 
reason, it may be hypothesized that CABG would offer greater protection against MI and 
cardiac death as compared to PCI, because a bypass graft could potentially protect the 
patient from the ischemia caused by rupture of a vulnerable plaques located proximal to a 
patent graft touchdown site. In contrast, PCI is not directed at mild plaques and treats a 
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smaller segment of the vessel. Thus in addition to myocardial ischemia burden, factors such 
as extent and distribution of vulnerable plaque, the progressive nature of the atherosclerotic 
disease process, extent of myocardial scar, ventricular function and improvements in 
medical therapy play a role in determining outcome. In addition, as mentioned earlier, most 
patients enrolled in these trials did not have moderate-severe ischemia.
The relatively high proportion of participants in the COURAGE and BARI-2D ancillary 
studies with residual moderate-severe ischemia after revascularization could be taken to 
indicate that the revascularization approach may not have been “complete”, i.e., not all 
ischemia-producing arterial segments may have been adequately treated. Some would 
suggest this could have contributed to neutral results. However, it must be noted that not all 
CAD is amenable to revascularization, particularly diffuse disease that may cause extensive 
ischemia, chronic total occlusions and distal disease. In addition, restenosis, stent thrombosis 
and graft occlusion contribute to residual ischemia during follow-up.
Variability in ischemia interpretation
The determination of ischemia severity by individual site stress imaging laboratories may 
not correspond perfectly to core lab interpretation. In the clinical trial setting, enrolling sites 
typically overestimate the ischemia severity as compared to a core laboratory. This may 
relate to core laboratory review of images in the absence of information about symptoms 
and, for exercise tests, exercise duration and ECG results. Thus a test showing mild ischemia 
by perfusion criteria in isolation may be interpreted as high risk after synthesis of imaging 
results with additional, risk parameters. This may explain the relatively low prevalence of 
moderate-severe ischemia in trials such as COURAGE and BARI-2D.
Trials addressing this and related questions
PROMISE and RESCUE Trials
The PROspective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial 
randomized 10,003 participants with recent onset symptoms to a strategy of initial stress 
testing or coronary CT angiography.48 Downstream management was not specified by 
protocol in this NHLBI-funded, multi-center trial. There was no difference between 
randomized groups in the primary endpoint of death, MI, unstable angina or major 
complications from CV procedures or testing. However, the included patients were at low 
risk of events, approximately 3% over 2 years. Revascularization was more common in the 
CT-assigned group, 6.2% vs. 3.2%; severity of ischemia in the stress testing group has not 
yet been reported.
The Randomized Evaluation of Patients with Stable Angina Comparing Utilization of 
Diagnostic Examination (RESCUE) trial will randomize approximately 4,300 participants to 
an initial diagnostic strategy of coronary CT angiography or stress nuclear imaging. 
(ClinicalTrials.gov NCT01262625) Unlike PROMISE, the RESCUE protocol specifies 
criteria for invasive coronary angiography in the SPECT imaging arm. The primary endpoint 
is major adverse cardiac events.
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PROMISE and RESCUE are novel and important for clinicians in that clinical outcomes are 
assessed according to a randomized imaging strategy. The two studies will provide 
complementary information because they use different types of stress testing and use of 
invasive angiography and revascularization varies from clinician-directed to protocol-
directed.
ISCHEMIA Trial
In recognition of the lack of conclusive evidence supporting ischemia-guided 
revascularization, current ACCF/AHA/SCAI PCI guidelines indicate that “the PCI and 
CABG guideline writing committees endorse the performance of the ISCHEMIA 
(International Study of Comparative Health Effectiveness with Medical and Invasive 
Approaches) trial, which will provide contemporary data on the optimal management 
strategy (medical therapy or revascularization with CABG or PCI) of patients with SIHD, 
including multivessel CAD, and moderate to severe ischemia.”49
Patients are being selected for this randomized, international trial primarily based on the 
presence of moderate-severe ischemia on stress testing at baseline, whether based on stress 
nuclear imaging, stress echocardiography stress cardiac MRI, or exercise tolerance testing 
alone [Table 2]. (ClinicalTrials.gov NCT01471522) Ischemia testing methods other than 
nuclear imaging were included to improve generalizability of trial results. Moderate 
ischemia criteria for the echo and CMR stress modalities were based on published studies 
that identified findings that were associated with an approximately 5% per year mortality, in 
alignment with the nuclear criterion.32 Ischemia tests are interpreted by central core 
laboratories. Participants are randomized to an invasive or conservative strategy. Both 
treatment groups receive intensive, goal-directed medical therapy as well as lifestyle 
counseling. The invasive strategy includes routine cardiac catheterization followed by 
revascularization, the mode of which (percutaneous or surgical) is selected according to 
ability to achieve relief of ischemia in all territories and suitability of the anatomy. The 
conservative strategy targets medical management alone, with cardiac catheterization 
reserved for participants with acute ischemic events or symptoms refractory to medical 
therapy.
A unique component of this trial is that the randomization occurs before cardiac 
catheterization, unlike all prior trials of revascularization. Many believe that once the patient 
is referred to angiography that the decision to undergo PCI or CABG is a foregone 
conclusion and that knowledge of coronary anatomy in COURAGE, BARI-2D and FAME 2 
biased enrollment and therefore results. In ISCHEMIA, blinded coronary CT angiography is 
performed before randomization in order to exclude patients with significant left main 
disease and those patients without obstructive CAD. (See Figure 2) There is not currently 
equipoise in the community regarding revascularization of patients with significant left main 
disease and patients without obstructive CAD would not be expected to benefit from a 
revascularization strategy. Patients with chronic kidney disease (estimated glomerular 
filtration rate less than 60 ml/min) are permitted to participate without a coronary CT 
angiogram if the treating physician does not suspect left main disease. Patients on dialysis 
and with advanced CKD are eligible. Those with an unacceptable degree of angina after 
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treatment with medical therapy will be excluded from participation, as will patients with 
EF<35%.
The aim of the trial is to determine whether the invasive strategy will be superior to the 
conservative strategy for the endpoint of cardiovascular death or MI over an average follow 
up of 4 years in this subset of SIHD patients with moderate-severe inducible ischemia. The 
study is powered for narrow confidence intervals as well as hypothesis testing, reflecting 
equipoise. The primary endpoint includes cardiovascular death rather than all-cause 
mortality because it is believed that the invasive strategy may not influence non-cardiac 
death. However, the definition of cardiovascular mortality is broad. The study definition of 
MI was designed to avoid counting of lower levels of peri-procedural troponin elevations 
which do not have prognostic significance. The universal definition of MI will also be 
assessed.
Randomization of 8,000 patients will take place at a projected 400 sites globally. The trial 
has been designed in an effort to build on the prior SIHD trials. Firstly, higher risk patients 
will be enrolled. Secondly, the coronary anatomy will not be known before randomization in 
either group and will remain blinded in the conservative group. Finally, revascularization 
will incorporate the modality judged to be most likely to relieve all ischemia, including 
hybrid procedures if needed.
It is hoped that this trial will determine whether ischemia burden effectively identifies 
patients who will have a lower risk of death or MI if subjected to a routine strategy of 
revascularization. At present, the answer is unknown.
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Figure 1. 
Rates of death or myocardial infarction among patients with core laboratory interpretation of 
baseline stress nuclear imaging in COURAGE, by ischemia severity.
Note that patients who did not return for follow up imaging were included in this analysis. 
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Figure 2. 
ISCHEMIA trial design schematic
1CCTA will be performed in most patients with eGFR >60 mL/min
2Exclude patients with LM disease or no obstructive disease. Those with no obstructive 
disease are considered for an ancillary study investigating the relationship between 
symptoms and ischemia over time
3OMT=Optimal medical therapy
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